Teva's Pivot to Growth Strategy, R&D priorities, and expectations remain unchanged; Company initiates search for successor
TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Dr. Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer, has decided to leave Teva and has accepted an offer outside the company. Dr. Hughes will remain with Teva through the coming months to support a seamless transition.
Effective immediately, David Gardiner, MD, Head of Innovative Medicines & Clinical Development, will serve as transition lead for R&D, reporting directly to Teva's President and Chief Executive Officer, Richard Francis, until a permanent successor is named. Teva is initiating a comprehensive search for a successor beginning immediately.
“Eric has made critical contributions to Teva and to the transformation of our R&D organization,” said Richard Francis, President and CEO of Teva. “He has helped build the pipeline, capabilities, and organization we presented at R&D Day last week and leaves Teva well positioned for its next chapter. Our strategy, priorities and expectations have not changed, and our focus remains on executing against the commitments we have made and continuing the momentum across our innovative pipeline.”
“I am incredibly proud of what our R&D organization accomplished to establish Teva as a truly innovative biopharma company and of the strong team we built,” said Dr. Hughes. “The progress we shared at R&D Day reflects the strength and depth of this organization and the exceptional science we developed together. I am deeply grateful to the entire team for their dedication, talent and partnership. It has been a privilege to lead them.”
Teva's R&D strategy and priorities remain unchanged, and the company remains focused on delivering on the commitments outlined in its November 11th R&D Day, including its ambition to generate $6–7 billion in innovative medicines revenue by 2030.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars, and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All in for Better Health. To learn more about how, visit www.tevapharm.com.